Investor's Business Daily on MSN
Edwards wavers analysts debate its earnings miss amid hefty TAVR investments
Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.
In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results